Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, Gaglani M, Columbus C, Gottlieb RL, Ghamande S, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Saeed S, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Khan A, Hough CL, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Parikh B, Exline MC, Vaughn IA, Ramesh M, Safdar B, Mosier J, Harris ES, Shapiro NI, Felzer J, Zhu Y, Grijalva CG, Halasa N, Chappell JD, Womack KN, Rhoads JP, Baughman A, Swan SA, Johnson CA, Rice TW, Casey JD, Blair PW, Han JH, Ellington S, Lewis NM, Thornburg N, Paden CR, Atherton LJ, Self WH, Dawood FS, DeCuir J.
Ma KC, et al. Among authors: blair pw.
Clin Infect Dis. 2024 Aug 6:ciae405. doi: 10.1093/cid/ciae405. Online ahead of print.
Clin Infect Dis. 2024.
PMID: 39107255